Piper Sandler downgrades CONMED rating to 'neutral' on lack of catalysts

Piper Sandler downgrades medical technology company CONMED CNMD.N to "neutral" from "overweight" rating citing lack of near-term catalysts

Brokerage says ongoing concerns around AirSeal performance and execution missteps have weighed on the stock for nearly two years

Piper Sandler cuts PT to $39, which still represents upside of 4.3% from last close

All of six brokerages rate the stock "hold"; their median PT is $43 - LSEG data

As of last close stock down ~7.9% YTD